Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on the deal. Keymed Biosciences (Chengdu) Co., Ltd. completed an out-licensing transaction with Belenos Biosciences, Inc.to exclusively...
Keymed Biosciences Inc.’s Out-Licensing Transaction With Belenos Biosciences
Zhejiang Expressway’s $860 Million H Shares Rights Issue
Clifford Chance advised infrastructure company Zhejiang Expressway Co., Ltd. Zhejiang Expressway Co., Ltd. completed its pioneer rights issue of H shares and domestic shares with gross proceeds...
Volkswagen Group’s Minority Investment in XPENG
Simpson Thacher & Bartlett is representing XPENG Inc. in the deal, Clifford Chance is advising Volkswagen Group. Volkswagen Group announced it has executed a strategic minority investment...
OneConnect’s Dual Primary Listing By Way of Introduction
Maples Group acted as Cayman Islands legal counsel, Cleary Gottlieb Steen & Hamilton acted as legal advisors to OCFT as to Hong Kong and US laws...
AIA Group’s US$1.86 Billion Acquisition Of a 24.99% Stake In China Post Life
Clifford Chance has advised China Post Life on the deal, while Debevoise & Plimpton advised AIA Group. China Post Life sold a 24.99% stake, post investment,...
Bilibili Inc.’s $2.6 Billion Secondary Listing
Walkers acted as Cayman Islands counsel to Bilibili Inc. in connection with its US$2.6 billion global offering of 25 million shares on the Main Board of...
HH&L Acquisition Co.’s US$414 Million IPO And NYSE Listing
Clifford Chance has advised HH&L Acquisition Co. on its formation, US$414 million IPO and listing on the New York Stock Exchange. HH&L Acquisition Co. is a special...
JD.com’s US$3.87 Billion Hong Kong IPO And Secondary Listing
Clifford Chance has advised the joint sponsors Bank of America, UBS and CLSA, and the underwriters on JD.com’s US$3.87 billion initial public offeringand secondary listing on...